When: Price reaches $675-$690 on expanding volume (≥3M shares) with RSI confirmation

Then: Trim position to 50% floor or below per 9/17 reflection

HOLD — zero new exposure until after Q3 earnings; existing holders should tighten trailing stop from 50 SMA ($593) to 10 EMA ($637); wait for pullback to $635-$650 zone or post-Q3 clean re-entry.

• Forward P/E of 23.9x is based on 48% earnings expansion forecast that hasn't materialized; consensus analyst target of ~$645 sits below current $658.76 price
• PEG ratio of 1.94 assumes accurate forward EPS but Q1 2026 $8.87B acquisition increased goodwill to $54.8B, creating integration risk that could derail EPS expansion
• Stock is 0.7% from 52-week high ($663.57) and upper Bollinger Band ($662.33) essentially tagged today's high ($660.43); RSI at 69.79 nearing historical exhaustion levels above 75-80
• Risk-reward asymmetry is 1:14 against at current levels — $593 support is 10% below vs. 3-6% upside to next resistance at $680-$700
• Trailing P/E of 35.5x in a 96% probability no-Fed-cuts regime means elevated real rates structurally compress premium multiples
• Mayo Clinic Precure JV is multi-year catalyst, not Q4 2026 catalyst; conflating long-term thesis with near-term trade setup creates position blowup risk
• Average daily range (ATR) of $15 means a 5% adverse move is a normal week, not a tail event — being 10% from 50 SMA support ($593) is not a buffer

→ vs aggressive: Forward P/E compression to 23.9x is analyst optimism, not delivered earnings — median price target below spot shows Street isn't buying the bull case

→ vs aggressive: PEG ratio 'reasonableness' ignores $8.87B acquisition integration risk that could make 23.9x forward P/E revert to 35x on smaller EPS

→ vs aggressive: Breakout-and-flag interpretation misreads the tape — stock ran into upper Bollinger Band ($662.33) at 52-week high ($663.57), not through it

→ vs aggressive: Management optimism into earnings is incentivized behavior, not conviction — merely hitting consensus ($645) will get stock sold

→ vs aggressive: High-for-longer rates compress, not support, premium multiples — 2022-2023 data shows growth multiples contracted in this regime, not expanded

→ vs aggressive: Treating $593 stop loss as 'free' ignores the stock is already 10% away with $15 ATR making 5% moves routine — that stop is closer than it appears

HOLD existing positions; enter new positions at 50-75% sizing in $635-650 zone only

• HOLD is the correct call for existing holders with stop at $593 (50 SMA), not the conservative analyst's $637 10 EMA stop
• New exposure sizing should be 50-75%, not full conviction (aggressive) or zero exposure (conservative)
• Entry zone for new positions is $635-650, representing a 7-9% drawdown from current levels with defined risk of $42-57 per share
• The relevant consensus price target is $645 (below current trading), not the TIKR bullish $839
• Higher-for-longer rate regime is a structural headwind for multiple expansion even for quality compounders like TMO
• TMO's beta of 0.85 makes it a defensive compounder with relative outperformance in risk-off scenarios
• Q3 earnings framework: hold through the print, don't add at current levels; beat=breakout to $680-700, miss/meet=pullback to $635-650 entry zone
• Management's bullish guidance increases downside risk, not confirms the thesis, due to structural CEO optimism incentives
• The 96% probability of no 2026 Fed cuts constrains multiple expansion but is not a death sentence for the equity

→ vs aggressive: Cites the TIKR midpoint of $839 as the relevant comp when the consensus target is $645 (below current price), creating no margin of safety

→ vs aggressive: Claims 96% no-cuts probability is a benign macro backdrop, but higher-for-longer constrains premium multiples even for quality compounders—it's a structural feature, not a talking point

→ vs aggressive: Treats bullish management guidance as thesis confirmation when CEO incentives are structurally optimistic, which actually raises the bar and increases downside risk

→ vs conservative: The 10 EMA trailing stop at $637 is approximately 1.5 ATRs ($15 daily range) below current price, guaranteeing whipsaw on normal 3-5% pullbacks that resolve higher

→ vs conservative: Absolute 'zero new exposure until after Q3 print' stance misses that $635-650 is already the defined entry zone, which could arrive before earnings

→ vs conservative: Treats multiple compression as absolute rather than relative—TMO's 0.85 beta means defensive outperformance in a market correction, not just downside